Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells

Surgery

Volumn 122, Issue 2, 1997, Pages 235-242

  Peiper, Matthias ^b   Goedegebuure, Peter S ^b   Eberlein, Timothy J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CELL PROLIFERATION; CELL SPECIFICITY; CONFERENCE PAPER; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; KILLER CELL; MONONUCLEAR CELL; PANCREAS CANCER; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE ACTIVATION; TARGET CELL;

EID: 0030761331     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(97)90014-3     Document Type: Conference Paper

References (25)

1. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994;180:1-4.
2. Goedegebuure PS, Douville LM, Li H, et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 1995;13:1939-49.
3. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988;25:1676-80.
4. Boon T. Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res 1992;58:177-210.
5. Peoples GE, Goedegebuure PS, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92:432-6.
6. Peiper M, Linehan DC, Ganguly E, et al. Lysis of pancreatic cancer cells by tumor-specific T-cells is associated with tumor cell-expression of HER2/neu. Surgical Forum 1995;46:140-2.
7. Yoshino I, Goedegebuure PS, Peoples GE, et al. HER2/neu-derived peptides are shared antigens among human non small cell lung cancer and ovarian cancer. Cancer Res 1994;54:3387-90.
8. Traversari C, van der Bruggen P, Luescher IF, et al. A non-apeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigene MZ2-E. J Exp Med 1992;176:1453-7.
9. Mentzner SJ, Rothlein R, Springer TA, Faller DV. Intercellular adhesion molecule-1 (ICAM-1) is involved in the cytolytic T lymphocyte interaction with a human synovial cell line. J Cell Physiol 1988;137:173-8.
10. Nishio M, Podack ER. Cooperation of B7 and ICAM-1 in induction of tumor-specific CTL; B7 transfection alone is ineffective [abstract]. FASEB J 1995;9:A515.
11. Steinman RM, Witmer-Pack M, Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993;329:1-9.
12. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996;183:7-11.
13. + T cell lines from native precursors. J Immunol 1994;153:996-1003.
14. Porgador A, Gilboa E. Bone-marrow-generated dendritic cells pulsed with class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995;182:255-60.
15. Linehan DC, Peoples GE, Hess DT, et al. In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour. Surg Oncol 1995;4:41-9.
16. Schoof DD, Selleck CM, Massaro AF, Jung SE, Eberlein TJ. Activation of tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex. Cancer Res 1990;50:1138-43.
17. Henderson RA, Michel H, Sakaguchi K. HLA-A21-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992;255:1264-6.
18. Peiper M, Goedegebuure PS, Linehan DC, et al. The HER2/neu derived peptide p654-662 is a TAA in human pancreatic cancer recognized by T lymphocytes. Eur J Immunol 1997;27:1115-23.
19. Fisk B, Savary C, Hudson JM, et al. Changes in an HER2/neu peptide upregulating HLA-A2 expression on both confirmational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction. J Immunother 1995;18:197-209.
20. Peoples GE, Schoof DD, Andrews VR, Goedegebuure PS, Eberlein TJ. T-cell recognition of ovarian cancer. Surgery 1993;114:227-34.
21. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 1994;194:2393-400.
22. Mayordomo II, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Medicine 1995;1:1297-305.
23. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918-26.
24. Steger MM, Maczek C, Grubeck-Loebenstein B. Morphologically and functionally intact dendritic cells can be derived from the peripheral blood of aged individuals. Clin Exp Immunol 1996;105:544-50.
25. Peoples GE, Goedegebuure PS, Andrews JVR, Schoof DD, Eberlein TJ. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 1993;151:5481-91.